Introduction
============

Metaplastic breast carcinoma (MBC) is a rare and heterogeneous type of neoplasm characterized by the histological presence of ≥2 cellular types, commonly a mixture of epithelial and mesenchymal components ([@b1-ol-0-0-6399]). The World Health Organization (WHO) recognized this subtype of breast cancer as a unique pathological entity in 2000, and its incidence is \<1% of all breast malignancies ([@b2-ol-0-0-6399],[@b3-ol-0-0-6399]). The key concept in the pathogenesis and development of MBC may be that epithelial to mesenchymal transition (EMT)-associated genes are differentially upregulated ([@b4-ol-0-0-6399]) and enriched in tumor-initiating cells ([@b5-ol-0-0-6399]).

Only a few large studies on MBC have been published to date ([@b6-ol-0-0-6399],[@b7-ol-0-0-6399]); however, MBC has long been recognized as a distinct histological type of breast cancer ([@b8-ol-0-0-6399]). Due to its low incidence rate and pathological variability, the clinical characteristics, prognostic significance and optimal treatment modalities are unclear and controversial. Certain reports have suggested that the prognosis of MBC is favorable, with survival similar to that of adenocarcinoma of a comparable stage ([@b9-ol-0-0-6399],[@b10-ol-0-0-6399]), whereas others consider that MBC may exhibit an aggressive course, with worse outcomes than those of triple-negative invasive ductal carcinoma ([@b11-ol-0-0-6399],[@b12-ol-0-0-6399]). MBCs usually present as large tumors that are negative for hormone receptors and rarely benefit from conventional chemotherapy or hormonal therapy ([@b13-ol-0-0-6399]). Although the incidence of axillary lymph node (LN) involvement is low, these tumors exhibit an increased risk of developing distant organ metastasis compared with infiltrating ductal carcinoma (IDC) ([@b14-ol-0-0-6399]). In clinical practice, MBC is usually treated based on the guidelines developed for IDC ([@b15-ol-0-0-6399]). The ideal treatment paradigm for MBC is unknown; thus, potential predictors of treatment efficacy must be explored.

The present study reviewed the clinical, pathological and biological characteristics of 69 patients with MBC who were diagnosed and treated at Tianjin Medical University Cancer Institute and Hospital (Tianjin, China), and evaluated the clinicopathological features, different therapeutic strategies and prognostic factors of survival.

Patients and methods
====================

### Patients

Among 30,053 patients who underwent surgery for breast cancer at Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) from January 1, 2002 to January 1, 2015, 69 (0.23%) patients were identified as MBC. All patients were females and their ages ranged from 28 to 89 years, with a median age of 53 years. Details concerning clinicopathological characteristics, surgical treatment, chemotherapy and radiation therapy (RT) were also gathered from the medical records.

In total, 53 cases received modified radical mastectomy (MRM), 9 cases received radical mastectomy (RM), 2 cases received segmental mastectomy and axillary dissection, and 5 cases received segmental mastectomy only. A total of 50 cases had received chemotherapy, 14 cases had received radiotherapy, and 8 cases with positive estrogen receptor (ER) or progesterone receptor (PR) expression had received adjuvant hormonal therapy. The pathological diagnosis was performed in accordance with the histological classification of tumors developed by the WHO ([@b16-ol-0-0-6399]) and clinical staging was based on the tumor-node-metastasis staging of breast cancer developed by the American Joint Committee on Cancer (AJCC, 7th edition) ([@b17-ol-0-0-6399]).

The diagnosis of MBC was conducted in the absence of an associated primary metaplastic cell type in a secondary site and in the absence of skin involvement. The pathologic material for each case of MBC was retrieved from the archive of the Department of Breast Cancer at the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) and reviewed.

### Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH)

Formalin-fixed paraffin embedded tissue sections were employed in each case using a standard protocol. IHC staining and FISH analysis were performed on tissue sections (3--4 µm) and tissue microarray slides. IHC staining (Benchmark XT; Ventana Medical Systems, Tucson, AZ, USA) was performed on tumor sections from 69 patients using the avidin-biotin-immunoperoxidase technique for ER (cat no. NCL-L-PGR-312; dilution, 1:100), PR (cat no. NCL-L-ER-6F11; dilution, 1:80) \[both from Novocastra, Leica Biosystems (Newcastle) Ltd., Newcastle Upon Tyne, UK\] and human epidermal growth factor receptor 2 (HER-2; cat no. 800-2996; dilution 1:300; Ventana Medical Systems). An iView DAB detection kit (Ventana Medical Systems) was used for secondary antibody. The FISH test was performed according to the Abbott/Vysis PathVysion HER2 DNA Probe kit (cat no. 30161060/02J01-030; Abbott Molecular Inc., Des Plaines, IL, USA) manufacturers protocol. The SpectrumOrange fluorophore-labeled DNA probe for the HER-2/neu gene locus and SpectrumGreen fluorophore-labeled α-satellite DNA probe for chromosome 17 from this kit were used. In total 2 separate fields of ≥20 cells were counted and an average of the results from the preselected tumor areas were used to create mean average gene and chromosomal counts, which were used to calculate the HER2:CEP17 signal ratio. Tumor cells from matching sites of IHC were scored for the number of red (HER2) and green (chromosome 17) signals. The slides were evaluated using an Olympus BX51 microscope (Olympus, Tokyo, Japan) with an oil-immersion objective lens and an appropriate filter set at magnification, ×100. The immunoreaction was evaluated independently by ≥2 pathologists.

The threshold used for positive ER and PR expression was 1% of nuclear staining in the total number of tumor cells stained. HER-2 immunoreactivity was evaluated on a standardized scale from 0--3 based on the intensity of staining of the cell membrane and the proportion of invasive tumor cells stained. Strong complete staining of the membrane in \>10% of tumor cells (score, 3+) was considered positive. Intensity patterns with scores 0--1+ were considered negative, and samples scored as 2+ were further assessed by FISH test where HER2/CEP17 ratio of \>2.0 was considered positive for HER2 gene amplification.

### Follow-up

Overall survival (OS) was defined as the time from the date of first surgery to the date of mortality or last follow-up. Disease-free survival (DFS) was defined as the duration of time between the date of first surgery and the date of first local recurrence or distant metastasis or last follow-up. For all patients, follow-up started from the date of operation. The patients were followed up in the Outpatients Department of Tianjin Medical University Cancer Institute and Hospital at 3 months intervals for the first year, at 6 months intervals for the following 2 years and then annually. All patients were followed up until mortality or the cut-off date of January 1, 2015. A total of 3 cases were lost to follow-up, and the median follow-up time was 37 months (range, 9--139 months). OS data were obtained from medical records or by telephone calls or letter communication. This study was approved by the Institutional Review Board of the Tianjin Medical University Cancer Institute and Hospital and written consent was obtained from all participants.

### Statistical analysis

All statistical analyses were carried out using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA) for Windows. Cumulative survival analysis of the patients was used to evaluate possible associations between survival and patient covariates. The Kaplan-Meier method and the log-rank test were used for univariate analysis, while the Cox proportional hazard model was applied for multivariate analysis. All tests were two sided. P\<0.05 or a 95% confidence interval (CI) that did not include 1 was considered to indicate a statistically significant difference.

Results
=======

### Clinicopathological characteristics

The clinical characteristics of MBC patients are summarized in [Table I](#tI-ol-0-0-6399){ref-type="table"}. Among the patients, squamous and sarcomatoid were the most common histological subtype, followed by adenosquamous, spindle cell and osseous/chondroid carcinoma. A total of 11 patients had a family history of cancer. The most common clinical presentation was a firm lump, which was noted in 66 patients, among which, 3 patients had a history of blood nipple discharge and other 3 patients had a history of blood nipple discharge with pain. Tumor sizes were determined by gross pathological examination, and ranged from 0.8 to 10.0 cm (mean, 3.7 cm; median, 3.5 cm). LN involvement was reported in 29.0% of the 69 MBC patients. Among all the MBC cases, 78.2% had triple-negative breast cancer (TNBC) tumors and 69.6% had basal-like type breast carcinomas.

### Treatment modalities

All patients received surgical treatment. The most common surgical procedure was MRM, which was performed in 53 patients. If required, patients would receive this treatment in combination with chemotherapy, radiotherapy and/or hormonal therapy post-surgery ([Table II](#tII-ol-0-0-6399){ref-type="table"}). All chemotherapy regimens and their outcomes in 50 patients are summarized in [Table III](#tIII-ol-0-0-6399){ref-type="table"}. The remaining 19 patients did not receive chemotherapy due to poor health or economic problems.

### Outcome, recurrence and prognosis

Up to the cut-off date for the analysis, 3 patients were lost to follow-up, 35 patients were still alive without recurrence and 28 patients succumbed to disease progression. In total, 20 patients experienced locoregional recurrence during the follow-up subsequent to surgery. Of the 20 patients with locoregional relapse, 13 relapses occurred in the chest wall, 4 relapses occurred in the ipsilateral breast and 3 relapses occurred in the ipsilateral axilla. Among 28 patients who developed distant metastasis during the follow-up, the most common organs involved were the lung (n=16), liver (n=9), bone (n=7), supraclavicular LNs (n=3) and brain (n=4). The 5-year DFS and OS rates were 52.2 and 60.2%, respectively.

### Univariate and multivariate analysis of OS and DFS

The univariate and multivariate analyses for the association between 5-year DFS and OS rates and clinicopathological characteristics are shown in [Table IV](#tIV-ol-0-0-6399){ref-type="table"}. Kaplan-Meier analysis and log-rank test revealed that T stage and LN status were significant predictors for DFS and OS in univariate analysis. Chemotherapy could significantly improve the 5-year OS rate in univariate analysis, whereas no significantly difference for the 5-year DFS rate was observed. The 5-year OS rate was 68.7% in the chemotherapy group and 37.2% in the non-chemotherapy group. When the above variables were analyzed by a Cox proportional hazard model, T stage and LN status remained significant independent predictors for DFS and OS. The hazard ratio for patients subjected to chemotherapy was 0.27 (95% CI, 0.11--0.67) for OS.

Furthermore, patients were stratified as LN positive (LN^+^) and LN negative (LN^−^). As shown in [Fig. 1](#f1-ol-0-0-6399){ref-type="fig"}, chemotherapy significantly improved the DFS in univariate analysis. In a subgroup analysis of the patients with LN^+^ group and LN^−^ group, chemotherapy significantly improved the DFS of LN^+^ patients, LN^−^ patients did not gain a significant survival benefit from chemotherapy. As shown in [Fig. 2](#f2-ol-0-0-6399){ref-type="fig"}, RT did not significantly improve the DFS in univariate analysis; however, it significantly improved the DFS of patients with tumors ≥5 cm or with \>4 metastatic axillary LNs.

Discussion
==========

MBC is an extremely rare malignancy and the current WHO 2012 classification distinguishes five subtypes of MBC ([@b16-ol-0-0-6399]). Previous studies reported that no significant difference was observed in terms of clinical outcome among patients with different MBC subtypes ([@b18-ol-0-0-6399],[@b19-ol-0-0-6399]). In the present study, there was no significant difference in OS or DFS among squamous cell carcinoma, spindle cell carcinoma, adenosquamous carcinoma or carcinosarcoma. As previously reported, MBC tends to occur in older females, and usually presents as a palpable mass that grows rapidly, which may indicate that MBC is an aggressive disease ([@b20-ol-0-0-6399]). A previous study reported that tumor size was best correlated with prognosis ([@b21-ol-0-0-6399]), whereas this finding was not consistent with another study ([@b22-ol-0-0-6399]). In the current study, 24.6% of patients presented with a palpable tumor at stage T3-4. Among them, 14 experienced relapse. By contrast, of the 52 cases with a palpable tumor at stage T1-2, 25 relapsed, and had a significant difference in their 5-year DFS and OS rates in univariate analysis. The tumor size acted as an independent prognostic factor in multivariate analysis for MBC patients. Previous studies have demonstrated axillary LN metastases in 22--31% of patients with MBC ([@b14-ol-0-0-6399],[@b23-ol-0-0-6399]). Despite this low rate, MBC patients with LN metastasis had a greater risk of developing metastatic disease and a poorer prognosis than IDC patients ([@b24-ol-0-0-6399],[@b25-ol-0-0-6399]). This may also support the concept that MBC is an aggressive tumor with a high risk of recurrence following primary therapy. In the current study, 29.0% of patients had axillary LN metastases, which is consistent with the majority of previous reports ([@b23-ol-0-0-6399]). In univariate analysis, LN status was a significant prognostic factor, while in multivariate analysis, LN positivity remained an independent risk factor for the 5-year DFS and OS rates. MBC patients with a large tumor size and LN positivity had a poor survival outcome. Therefore, early diagnosis and treatment of this rare entity is critical to patient prognosis.

The majority of MBC cases have similar characteristics. MBCs have a basal-like immunophenotype, and rarely overexpress hormone receptors and HER-2 ([@b26-ol-0-0-6399]). In a study on 2,338 patients with MBC, 21.0% were hormone receptor positive, and hormone receptor positivity does not improve prognosis ([@b27-ol-0-0-6399]). According to the present study, 78.2% of patients had TNBC tumors and 69.6% had basal-like type breast carcinomas, which may help to explain the commonly observed higher grade and increased rapid growth of MBCs compared with IDCs. In addition, there was no significant difference in the 5-year DFS or OS rates between the TNBC group and the non-TNBC group in the present study.

As MBC patients typically present with large tumors, \>70% of patients with MBC present with AJCC stage II ([@b14-ol-0-0-6399]) and a higher percentage of patients with MBC receive mastectomy rather than lumpectomy ([@b3-ol-0-0-6399],[@b9-ol-0-0-6399]). However, a previous study observed no difference in OS or DFS in MBC patients treated with mastectomy compared with those treated with lumpectomy, even upon controlling for known prognostic factors ([@b22-ol-0-0-6399]). In the present study, the majority of cases were stage II and received MR/MRM. There was no significant difference between MRM/RM and other type of operation. Taking into account the large tumor size, and the somewhat refractory nature of the tumor to standard chemotherapy and hormonal therapy, MRM/RM was selected as an optimal surgical treatment; however, breast conservative surgery and segmental mastectomy cannot be precluded in certain eligible patients.

Several MBC cases have been shown to exhibit a good response to chemotherapy ([@b28-ol-0-0-6399]). Takuwa *et al* ([@b29-ol-0-0-6399]) reported that a patient had a good response to platinum combined with taxane or anthracycline therapy. The majority of previous studies, however, have revealed an ineffective response of MBC to chemotherapy ([@b30-ol-0-0-6399]). Compared with the response rates of stage-matched female patients with IDC, those with MBC receiving chemotherapy had lower response rates to the chemotherapy regimens ([@b30-ol-0-0-6399],[@b31-ol-0-0-6399]). A single-institute retrospective study reported that tumor response to systemic chemotherapy remains generally poor, since only 17.6% of patients who received taxane-based chemotherapy exhibited a positive response ([@b32-ol-0-0-6399]). The reason for the ineffective response to chemotherapy may be that MBCs are part of the spectrum of basal-like breast carcinomas and display a myoepithelial and EMT-like molecular makeup ([@b26-ol-0-0-6399]). Basal-like tumors and breast cancer 1 (BRCA1)-associated breast cancer tumors were reported to be similar according to microarray and immunohistochemical analyses ([@b33-ol-0-0-6399],[@b34-ol-0-0-6399]). In BRCA1-associated breast cancer and basal-like tumors, current standard anthracycline- and taxanes-containing chemotherapy regimens were prone to ineffectiveness ([@b35-ol-0-0-6399]). However, these regimens were able to sensitize tumors with homologous recombination DNA repair defects to platinum salts and poly ADP-ribose polymerase (PARP) inhibitors ([@b36-ol-0-0-6399]). The results from two randomized trials indicated that cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy significantly improved treatment outcome in patients with triple-negative, node-negative breast cancer ([@b37-ol-0-0-6399]). In the present study, MBC patients with LN^−^ did not benefit from chemotherapy. By contrast in MBC patients with LN^+^, the 5-year OS and DFS rates significantly improved with chemotherapy. Among the different chemotherapy regimens, CMF and cisplatin-based regimens may be effective to certain subgroups of MBC patients, as suggested by their relatively long median 5-year DFS, although no significant survival benefit from different regimens was observed in these patients. These findings would suggest that a subset of MBC patients may potentially experience a curative benefit from systemic chemotherapy, but they also support the chemorefractory behavior of these tumors. Platinum salts combined with PARP inhibitors could be used for clinical treatment. The limitations of the present study include: i) The majority of patients who did not receive chemotherapy were elderly patients with a relative poor health; ii) a small sample was analyzed; and iii) the positive rate of LN was low. Therefore, additional clinical data and multicenter studies are required to confirm the present results.

Tseng and Martinez ([@b38-ol-0-0-6399]) described patients with MBC who had received RT and experienced a benefit in terms of OS and DFS, which suggests that patients undergoing breast conservation surgery and those with tumors ≥5 cm or with \>4 metastatic axillary LNs undergoing mastectomy should receive RT. Another study suggested that RT, regardless of the type of surgery, should be considered as a part of the therapy for patients with MBC ([@b15-ol-0-0-6399]). In the present study, survival analysis did not reveal a significant survival benefit from RT, since no significant differences were observed in the risk of recurrence for those patients treated with adjuvant RT and not treated with RT. However, in MBC patients with tumors ≥5 cm or with \>4 metastatic axillary LNs who received RT, the 5-year OS and DFS rates significantly improved. Genomic profiling of MBC tumors has shown downregulation of DNA repair pathways, including the BRCA1, phosphatase and tensin homolog and topoisomerase 2-α pathways, which may explain the lower incidence of LN spread and sensitivity towards RT of MBC ([@b39-ol-0-0-6399]). The present results demonstrated that RT should be considered as a component of multimodality therapy for MBC patients with tumors ≥5 cm or with \>4 metastatic axillary LNs. However, since the present study is a retrospective analysis with a low LN metastasis rate and a small sample receiving RT, a larger multicenter study is required to draw definitive conclusions.

In MBC patients, the positive expression of hormone receptors has been reported to be low ([@b40-ol-0-0-6399]). However, hormone receptor positivity does not improve the prognosis of MBC patients ([@b27-ol-0-0-6399]), since in a retrospective study, the non-TNBC group of MBC patients had a poor prognosis compared with that of the TNBC group ([@b41-ol-0-0-6399]). MBC patients often show little or no response to adjuvant hormonal therapy or HER-2-targeted treatment (trastuzumab) ([@b42-ol-0-0-6399]). In the present study, only 8 patients had been prescribed tamoxifen/aromatase inhibitors therapy, as they had ER- and/or PR-positive tumors. Of these patients, 3 relapsed at 17, 28 and 62 months after surgery, respectively. The tumors in 9 patients were HER-2^+^; however, only 2 patients were treated with trastuzumab due to financial reasons. Of these 2 patients, 1 developed lung and brain metastases 33 months after surgery and succumbed to the disease 7 months later, while the other patient is still alive and free of recurrence at 43 months after surgery. Due to the high incidence of TNBC in MBC, hormonal therapy or HER-2-targeted treatment is unlikely to influence the survival of MBC patients.

In conclusion, MBC is a clinically aggressive subtype of breast cancer associated with large tumor size and a high proportion of TNBC and basal-like tumors. Hormonal therapy or HER-2-targeted treatment is unlikely to influence survival due to the high incidence of TNBC tumors. Chemotherapy may be recommended for certain subtype of MBC patients with LN positivity. Cisplatin-based regimens and CMF regimens may be effective in certain subgroups. MBC patients with tumors ≥5 cm or with \>4 metastatic LNs could benefit from RT. Other therapeutic strategies, including mechanistic target of rapamycin, androgen receptor and transforming growth factor-β, should strongly be considered in clinical trials of innovative therapeutic regimens. However, the present study possess certain limitations: This is a retrospective analysis with a small sample size and not a prospective study; a multicenter study would be preferable in the future. There may have also been a lack of uniformity as the surgery was performed by different surgeons. To additionally clarify the characteristics and prognosis of MBC patients, and in order to improve treatment, the systematic study of a large number of cases with long-term follow-up will be necessary.
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###### 

Clinicopathological features of patients with metaplastic carcinoma of the breast.

                         Patients   
  ---------------------- ---------- ------
  Age, years                        
    \<50                 22         31.9
    ≥50                  47         68.1
  Menopausal status                 
    Premenopausal        26         37.7
    Postmenopausal       43         63.3
  Tumor stage                       
    T1                   10         14.5
    T2                   42         60.9
    T3                   12         17.4
    T4                   5          7.2
  Lymph node stage                  
    N0                   44         63.8
    N1                   14         20.3
    N2                   5          7.2
    N3                   1          1.4
    Unknown ER status    5          7.2
    Negative             59         85.5
    Positive             10         14.5
  PR status                         
    Negative             63         91.3
    Positive             6          8.70
  HER-2 status                      
    Negative             60         87.0
    Positive             9          13.0
  Subtype                           
    Squamous cell        22         31.9
    Adenosquamous cell   14         20.3
    Spindle cell         9          13.0
    Chondroid            2          2.9
    Sarcomatoid          22         31.9

ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2.

###### 

Treatment modalities.

                                      Patients   
  ----------------------------------- ---------- ------
  Breast surgery                                 
    Modified-radical mastectomy       53         76.8
    Radical mastectomy                9          13.0
    Breast-conserving surgery with    2          2.9
    Axillary lymph nodes dissection              
    Segmental mastectomy              5          7.2
  Chemotherapy                                   
    Yes                               50         72.5
    No                                19         27.5
  Radiation therapy                              
    Yes                               14         20.3
    No                                55         79.7
  Adjuvant hormonal therapy                      
    Yes                               8          11.6
    No                                61         88.4
  Adjuvant trastuzumab                           
    Yes                               2          2.9
    No                                67         97.1

###### 

Adjuvant chemotherapy regimens and their outcomes.

  Chemotherapy regimens   Patients, no.   5-year DFS, %   MST
  ----------------------- --------------- --------------- -----------------------------------------------------------------------------------------------------------------
  CMF                       9             62.2            6 relapse free at 122, 89, 73, 34, 27 and 22 months, respectively; 3 relapsed
  AT/ET/TAC/TEC           31              52.3            14 relapse free at 133, 99, 89, 76, 67, 66, 63, 62, 61, 60, 46, 41, 26 and 20 months, respectively; 17 relapsed
  NP/CP/TP                10              70.0            6 relapse free at 139, 105, 79, 76, 60 and 24 months, respectively; 4 relapsed

DFS, disease-free survival; MST, median survival time; CMF cyclophosphamide, methotrexate and 5-fluorouracil; AT, docetaxel and adriamycin; ET, epirubicin and docetaxel; TAC, docetaxel, adriamycin and cyclophosphamide; TEC, docetaxel, epirubicin and cyclophosphamide; NP, vinorelbine and cisplatin; CP, cyclophosphamide and cisplatin; TP, docetaxel and cisplatin.

###### 

Analysis of the prognostic factors for DFS and OS.

                                       5-year DFS          5-year OS                                                                               
  ------------------------------------ ------------------- ----------- ------------------- ------- ------------------- ------- ------------------- -------
  Age, years                                               0.213                                                       0.380                       
    \<50                               1                                                           1                                               
    ≥50                                1.63 (0.76--3.51)                                           1.45 (0.63--3.31)                               
  Menopausal status                                        0.153                                                       0.165                       
    Premenopausal                      1                                                           1                                               
    Postmenopausal                     1.70 (0.82--3.51)                                           1.76 (0.79--3.93)                               
  T stage                                                  0.001                           0.001                       0.003                       0.001
    T1-2                               1                               1                           1                           1                   
    T3-4                               3.18 (1.57--6.42)               4.09 (1.84--9.06)           3.27 (1.51--7.07)           3.90 (1.71--8.90)   
  LN stage                                                 0.026                           0.016                       0.013                       0.028
    LN^−^                              1                               1                           1                           1                   
    LN^+^                              2.21 (1.01--4.45)               2.62 (1.20--5.72)           2.68 (1.24--5.81)           2.45 (1.10--5.44)   
  Hormone receptor expression status                       0.289                                                       0.250                       
    Negative                           1                                                           1                                               
    Positive                           0.57 (0.20--1.62)                                           0.49 (0.25--1.65)                               
  Chemotherapy                                             0.096                                                       0.010                       0.005
    No                                 1                                                           1                           1                   
    Yes                                0.52 (0.24--1.12)                                           0.33 (0.14--0.77)           0.27 (0.11--0.67)   
  Radiotherapy                                             0.539                                                       0.582                       
    No                                 1                                                           1                                               
    Yes                                1.27 (0.59--2.74)                                           1.26 (0.55--2.89)                               
  Hormonal therapy                                         0.240                                                       0.359                       
    No                                 1                                                           1                                               
    Yes                                0.49 (0.15--1.61)                                           0.57 (0.17--1.90)                               

P\<0.05 was considered to indicate a statistical significant value. OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval.
